Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.

Glover M, Smerdon GR, Andreyev HJ, Benton BE, Bothma P, Firth O, Gothard L, Harrison J, Ignatescu M, Laden G, Martin S, Maynard L, McCann D, Penny CEL, Phillips S, Sharp G, Yarnold J.

Open source

DOI
10.1016/s1470-2045(15)00461-1
Published
2015-12-17
Container
Lancet Oncol
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-15-00461-1,
  title = {Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.},
  author = {Glover M and  Smerdon GR and  Andreyev HJ and  Benton BE and  Bothma P and  Firth O and  Gothard L and  Harrison J and  Ignatescu M and  Laden G and  Martin S and  Maynard L and  McCann D and  Penny CEL and  Phillips S and  Sharp G and  Yarnold J.},
  year = {2016},
  journal = {Lancet Oncol},
  doi = {10.1016/s1470-2045(15)00461-1},
  url = {https://doi.org/10.1016/s1470-2045(15)00461-1}
}

RIS

TY  - JOUR
TI  - Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.
AU  - Glover M
AU  -  Smerdon GR
AU  -  Andreyev HJ
AU  -  Benton BE
AU  -  Bothma P
AU  -  Firth O
AU  -  Gothard L
AU  -  Harrison J
AU  -  Ignatescu M
AU  -  Laden G
AU  -  Martin S
AU  -  Maynard L
AU  -  McCann D
AU  -  Penny CEL
AU  -  Phillips S
AU  -  Sharp G
AU  -  Yarnold J.
PY  - 2016
JO  - Lancet Oncol
DO  - 10.1016/s1470-2045(15)00461-1
UR  - https://doi.org/10.1016/s1470-2045(15)00461-1
ER  - 

APA

M, G., GR, S., HJ, A., BE, B., P, B., O, F., L, G., J, H., M, I., G, L., S, M., L, M., D, M., CEL, P., S, P., G, S., & J., Y. (2016). Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.. Lancet Oncol. https://doi.org/10.1016/s1470-2045(15)00461-1

Source records